Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 10—October 2020

Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine against Invasive Pneumococcal Disease in Adults, Japan, 2013–2017

Reiko Shimbashi, Motoi SuzukiComments to Author , Bin Chang, Hiroshi Watanabe, Yoshinari Tanabe, Koji Kuronuma, Kengo Oshima, Takaya Maruyama, Hiroaki Takeda, Kei Kasahara, Jiro Fujita, Junichiro Nishi, Tetsuya Kubota, Keiko Tanaka-Taya, Tamano Matsui, Tomimasa Sunagawa, Kazunori Oishi, and Adult IPD Study Group
Author affiliations: National Institute of Infectious Diseases, Tokyo, Japan (R. Shimbashi, M. Suzuki, B. Chang, K. Tanaka-Taya, T. Matsui, T. Sunagawa, K. Oishi); Tohoku University Graduate School of Medicine, Miyagi, Japan (R. Shimbashi, M. Suzuki, K. Oshima); Kurume University School of Medicine, Fukuoka, Japan (H. Watanabe); Niigata Prefectural Shibata Hospital, Niigata, Japan (Y. Tanabe); Sapporo Medical University School of Medicine, Hokkaido, Japan (K. Kuronuma); National Hospital Organization Mie National Hospital, Mie, Japan (T. Maruyama); Yamagata Saisei Hospital, Yamagata, Japan (H. Takeda); Nara Medical University, Nara, Japan (K. Kasahara); Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan (J. Fujita); Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan (J. Nishi); Kochi Medical School, Kochi University, Kochi, Japan (T. Kubota); Toyama Institute of Health, Toyama, Japan (K. Oishi)

Main Article

Table 2

Overall and serotype-specific effectiveness of PPSV23 against invasive pneumococcal disease in adults >20 years of age, Japan, 2013–2017*

Serotype No. cases No. controls Crude VE, % (95% CI) Adjusted VE,† % (95% CI)
PPSV23 serotype 746 375 46.0 (17.8 to 64.5) 42.2 (13.4 to 61.4)
PCV13, non–6A serotype 392 375 40.6 (3.8 to 63.3) 35.3 (−8.4 to 61.5)
PPSV23, non–PCV13 serotype 354 375 51.7 (18.7 to 71.3) 44.5 (9.6 to 65.9)
Serotype 3 152 375 43.1 (−11.9 to 71.1) 34.1 (−34.4 to 67.7)
Serotype 19A 111 375 72.7 (29.1 to 89.5) 70.3 (13.3 to 89.8)
Serotype 12F 99 375 80.2 (34.4 to 94.0) 70.8 (1.0 to 91.4)
Serotype 22F 83 375 34.1 (−47.1 to 70.5) 22.7 (−88.8 to 68.4)
Serotype 10A 80 375 75.7 (19.2 to 92.7) 73.6 (5.9 to 92.6)
Serotype 11A/E 41 375 30.7 (−106.7 to 76.8) 20.7 (−145.4 to 74.4)
Serotype 7F 30 375 31.5 (−138.6 to 80.3) 22.4 (−176.8 to 78.2)

*BMI, body mass index; PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine; VE, vaccine effectiveness.
†Adjusted for sex, age, prefecture, year, season, BMI group, underlying conditions, and smoking history with clustering by public health center.

Main Article

Page created: August 05, 2020
Page updated: September 17, 2020
Page reviewed: September 17, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.